Video Archives

Updates in Prostate Cancer Biomarkers

Posted by Matthew R. Cooperberg, MD, MPH | Sep 2022

Matthew R. Cooperberg, MD, MPH, Professor of Urology and Epidemiology & Biostatistics and Helen Diller Family Chair in Urology at the University of California, San Francisco, addresses prostate-specific antigen (PSA) testing and explains that a PSA below the median has a very strong negative predictive value (NPV) in terms of meaningful cancer. He asserts that, when combined with secondary biomarker testing before biopsy, early baseline PSA can be very effective in terms of risk assessment. He also explains that as research on biomarkers evolves, the field will get closer to being able to use genomic information derived from the primary tumor to make initial and follow-on treatment decisions.

How to Integrate PSMA PET Findings Into Treatment Algorithms

Posted by Jérémie Calais, MD, PhD | Sep 2022

Jérémie Calais, MD, MSc, Associate Professor of Nuclear Medicine and Theranostics in the Department of Molecular and Medical Pharmacology at the University of California, Los Angeles (UCLA), Director of the UCLA Theranostics Program, and Director of the Clinical Research Program of the Ahmanson Translational Theranostics Division discusses how to integrate prostate-specific membrane antigen (PSMA) positron emission tomography (PET) findings into treatment algorithms. Dr. Calais explains that PSMA PET results in new staging categories, has predictive value, and has value in response assessment. He emphasizes that inclusion criteria of randomized phase-3 trials must include PSMA PET staging/screening/selection for PSMA PET to be integrated into treatment algorithms.

Gary Onik, MD, and Winston E. Barzell, MD, on the Origins of Prostate Focal Therapy and Imaging

Posted by E. David Crawford, MD | Sep 2022

E. David Crawford, MD, interviews Gary Onik, MD, and Winston E. Barzell, MD, on the origins of prostate cancer focal therapy.

Ernest Shackleton and Urologic Practices

Posted by Neil H. Baum, MD | Sep 2022

Grand Rounds in Urology Contributing Editor Neil H. Baum, MD, Professor of Urology at Tulane Medical School, offers advice to urologic clinicians on leading during uncertain times. Through the lens of adventurer Ernest Shackelton, Dr. Baum illustrates how providing excellent patient care involves responding to new information, maintaining morale, and leading by example.

Germline Genetics and Prostate Cancer Evolution and Aggressivity

Posted by Paul Boutros, PhD, MBA | Sep 2022

Paul C. Boutros, PhD, MBA, examines germline genetics and urine characteristics of prostate cancer and how these relate to aggression.Paul C. Boutros, PhD, MBA, examines germline genetics and urine characteristics of prostate cancer and how these relate to aggression.